Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ASN 2025

American Society of Nephrology (ASN) - Kidney Week 2025

November 5 - 9, 2025

  1. All
  2. Chronic Kidney Disease
  3. FARXIGA (dapagliflozin)
  4. Hypertension
  5. Heart Failure/Chronic Kidney Disease
  6. LOKELMA (Sodium zirconium cyclosilicate)

HTML

Association between erythrocyte indices and roxadustat response in chronic kidney disease patients with anemia: ROXSTAR registry secondary analysis

HTML

Evaluating the economic impact of CKD patients on Germany's healthcare system: A 2023 claims data analysis

HTML

Exploring gender differences: CKD prevalence, diagnosis and treatment in hypertensive German patients – Insights from the InspeCKD study

PDF

Harnessing AI and clinical guidelines to identify at-risk CKD patients and optimize management of CKD in the US

HTML

Innovative visualization of treatment effects in kidney disease trials using hierarchical composite endpoints

PDF 

Risk of CKD progression in a real-world population eligible for the ZENITH-High Proteinuria trial

HTML

Roxadustat response by inflammation/iron status subgroups in peritoneal dialysis patients with renal anemia: A secondary analysis of the NANLING study

PDF

Association of circulating protein levels with kidney outcome and effects of dapagliflozin: Proteomics analysis from DAPA-CKD

HTML

Cardio-kidney effects of dapagliflozin in patients at elevated cardiovascular risk with or without type 2 diabetes

HTML

Efficacy, mechanisms and safety of SGLT2 inhibitors in kidney transplant recipients

HTML

Sex differences in SGLT2i use complicating a treatment optimization program in a large network of nephrology practices

PDF

BP and urine albumin-to-creatinine ratio lowering by baxdrostat in participants in the FigHTN trial

PDF

Burden of proteinuria in patients with chronic kidney diseases: Insights from the iCaReMe global registry

PDF

Kidney outcomes and mortality in patients with comorbid chronic kidney disease and heart failure (the CaRe study)

PDF

Effects of sodium zirconium cyclosilicate on volume status in hemodialysis: Post hoc analysis from the DIALIZE-Outcomes trial

HTML

Management of hyperkalemia: Real-world insights from US patients and healthcare professionals in the TRACK study

PDF

Treatment strategies in de novo vs recurrent hyperkalemia: TRACK study insights

HTML

Association between erythrocyte indices and roxadustat response in chronic kidney disease patients with anemia: ROXSTAR registry secondary analysis

HTML

Evaluating the economic impact of CKD patients on Germany's healthcare system: A 2023 claims data analysis

HTML

Exploring gender differences: CKD prevalence, diagnosis and treatment in hypertensive German patients – Insights from the InspeCKD study

PDF

Harnessing AI and clinical guidelines to identify at-risk CKD patients and optimize management of CKD in the US

HTML

Innovative visualization of treatment effects in kidney disease trials using hierarchical composite endpoints

PDF 

Risk of CKD progression in a real-world population eligible for the ZENITH-High Proteinuria trial

HTML

Roxadustat response by inflammation/iron status subgroups in peritoneal dialysis patients with renal anemia: A secondary analysis of the NANLING study

PDF

Association of circulating protein levels with kidney outcome and effects of dapagliflozin: Proteomics analysis from DAPA-CKD

HTML

Cardio-kidney effects of dapagliflozin in patients at elevated cardiovascular risk with or without type 2 diabetes

HTML

Efficacy, mechanisms and safety of SGLT2 inhibitors in kidney transplant recipients

HTML

Sex differences in SGLT2i use complicating a treatment optimization program in a large network of nephrology practices

PDF

BP and urine albumin-to-creatinine ratio lowering by baxdrostat in participants in the FigHTN trial

PDF

Burden of proteinuria in patients with chronic kidney diseases: Insights from the iCaReMe global registry

PDF

Kidney outcomes and mortality in patients with comorbid chronic kidney disease and heart failure (the CaRe study)

PDF

Effects of sodium zirconium cyclosilicate on volume status in hemodialysis: Post hoc analysis from the DIALIZE-Outcomes trial

HTML

Management of hyperkalemia: Real-world insights from US patients and healthcare professionals in the TRACK study

PDF

Treatment strategies in de novo vs recurrent hyperkalemia: TRACK study insights

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States